Mirvetuximab soravtansine – November 2025

• Brand names:
  • Elahere®
• Pharmaceutical Company:
  • ABBVIE PTY LTD
• Condition/Indication: Epithelial ovarian, fallopian tube or primary peritoneal cancer
• Meeting Date: November 2025
• Public Summary Document (PSD) July 2025 November 2025 PBAC Meetings – (PDF 1.4MB)
• Public Summary Document (PSD) July 2025 November 2025 PBAC Meetings – (Word 653KB)

Related Public Summary Documents

• Mirvetuximab soravtansine – July 2025